Network Nutrition-IMCD assists in the research of herbal medicines in Alzheimer’s disease.
Alzheimer’s disease (AD) is a global burden and is the most common neurodegenerative disease in the aging population. According to the 2013 World Population and Aging report, “The global share of older people (aged 60 years or over) increased from 9.2% in 1990 to 11.7% in 2013 and will continue to grow as a proportion of the world population, reaching 21.1 per cent by 2050.” Other specific findings in the aging population are that the share of people aged 80 and over will reach 19% in 2050.
This trend is partly the result of living longer and healthier lives, but also because chronic and degenerative diseases are more common at older ages. Late-onset form of AD account for 50-70% of all cases of dementia and as the Network Nutrition-IMCD study suggests this includes those caused by drug-induced conditions, such as alcoholism. AD affects 10-15% of people aged 65 or older.
Dr. Suresh Govindaraghavan, the Network Nutrition-IMCD Research & Development Manager has made a remarkable contribution to the study which was published in CNS & Neurological Disorders – Drug Targets (2014) by recommending natural compounds as therapeutic agents against chronic inflammation in AD. The review considers omega 3 polyunsaturated fatty acids, and quality herbal extracts available from Network Nutrition such as Green Tea (catechins and proanthocyanidins), Turmeric (curcumin), Brahmi (bacosides) and Ginkgo (ginkgo flavone glycosides). These secondary metabolites have been shown to have anti-inflammatory, antioxidant, neuroprotective, and cognitive-enhancing effects. The evidence may suggest the increased consumption of these compounds may lead to a safe strategy to delay the onset of AD. Although further study is required, these demonstrate promising remedy for this disease.